References - Therapeutic Strategies in Cancer Biology and Pathology - page 219

Joost, S., Almada, L.L., Rohnalter, V., Holz, P.S., Vrabel, A.M., Fernandez-Barrena, M.G.,
et al., 2012. GLI1 inhibition promotes epithelial-to-mesenchymal transition in pancreatic
cancer cells. Cancer Res. 72, 88-99.
Jouppila-Matto, A., Narkio-Makela, M., Soini, Y., Pukkila, M., Sironen, R., Tuhkanen, H.,
et al., 2011. Twist and snai1 expression in pharyngeal squamous cell carcinoma stroma is
related to cancer progression. BMC Cancer 11 (350)
Jung, H., Seong, H.A., Ha, H., 2007. NM23-H1 tumor suppressor and its interacting partner
STRAP activate p53 function. J. Biol. Chem. 282, 35293-35307.
Jung, S., Park, R.H., Kim, S., Jeon, Y.J., Ham, D.S., Jung, M.Y., et al. 2010. Id proteins facili-
tate self-renewal and proliferation of neural stem cells. Stem. Cell Develop 19, 831-841.
Kang, H., Suh, J.Y., Jung, Y.S., Jung, J.W., Kim, M.K., Chung, J.H., 2011a. Peptide switch is
essential for Sirt1. Mol. Cell. 44, 203-213.
Kang, H.S., Baba, T., Mandai, M., Matsumura, N., Hamanishi, J., Kharma, B., et al., 2011b.
GPR54 is a target for suppression of metastasis in endometrial cancer. Mol. Cancer Ther.
10, 580-590.
Kang, M., Choi, S., Jeong, S.J., Lee, S.A., Kwak, T.K., Kim, H., et al., 2012a. Cross-talk
between TGF beta 1 and EGFR signalling pathways induces TM4SF5 expression and
epithelial-mesenchymal transition. Biochem. J. 443, 691-700.
Kang, M., Jeong, S.J., Park, S.Y., Lee, H.J., Kim, H.J., Park, K.H., et al., 2012b. Antagonistic
regulation of transmembrane 4L6 family member 5 attenuates fibrotic phenotypes in
CCL94)-treated mice. FEBS J. 279, 625-635.
Kano, M., Seki, N., Kikkawa, N., Fujimura, L., Hoshino, I., Akutsu, Y., et al., 2010. miR-145,
miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squa-
mous cell carcinoma. Int. J. Cancer 127, 2804-2814.
Kaproth-Joslin, K.A., Li, X., Reks, S.E., Kelley, G.G., 2008. Phospholipase C delta 1 regu-
lates cell proliferation and cell-cycle progression from G(1)-to S-phase by control of cyc-
lin E-CDK2 activity. Biochem. J. 415, 439-448.
Karadedou, C.T., Gomes, A.R., Chen, J., Petkovic, M., Ho, K.K., Zwolinska, A.K., et al.,
2012. FOXO3a represses VEGF expression through FOXM1-dependent and -independ-
ent mechanisms in breast cancer. Oncogene 31, 1845-1858.
Karapanagiotou, E.M., Dilana, K.D., Gkiozos, I., Gratsias, I., Tsimpoukis, S., Polyzos, A.,
et al., 2011. Metastin is not involved in metastatic potential of non-small cell lung cancer.
Med. Oncol. 28, 559-564.
Kapinas, K., Delany, A.M., 2011. MicroRNA biogenesis and regulation of bone remodelling.
Arthritis Res. Ther. 13, 220.
Katagiri, F., Nagai, K., Kida, A., Tomita, K., Oishi, S., Takeyama, M., et al., 2009. Clinical
significance of plasma metastin level in pancreatic cancer patients. Oncol. Rep. 21,
815-819.
Katiyar-Agarwal, S., Morgan, R., Dahlbeck, D., Borsani, O., Villegas, A., Zhu, J.K., et al.,
2006. A pathogen inducible endogenous siRNA in plant immunity. Proc. Natl. Acad. Sci.
U.S.A. 103, 18002-18007.
Katoh, Y., Katoh, M., 2006. Comparative integromics on FAT1, FAT2, FAT3 and FAT4. Int. J.
Mol. Med. 18, 523-528.
Katoh, Y., Katoh, M., 2008. Hedgehog signaling, epithelial-to-mesenchymal transition and
miRNA (Review). Int. J. Mol. Med. 22, 271-275.
Katoh, Y., Katoh, M., 2009. Integrative genomic analyses on GLI1: positive regulation of
GLI1 by Hedgehog-GLI, TGF beta-Smads, and RTK-PI3K-AKT signals, and negative
regulation of GLI1 by Notch-CSL-HES/HEY, and GPCR-Gs-PKA signals. Int. J. Oncol.
35, 187-192.